Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin/aspirin/ramipril - Ferrer Internacional

Next Previous
Drug Profile

Atorvastatin/aspirin/ramipril - Ferrer Internacional

Alternative Names: Aspirin/ramipril/atorvastatin; Atorvastatin/acetylsalicylic acid/ramipril; Atorvastatin/ASA/ramipril; Ramipril/atorvastatin/aspirin; Trinomia

Latest Information Update: 21 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferrer
  • Developer Ferrer; HLS Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Cardiovascular therapies; Heart failure therapies; Heterocyclic bicyclo compounds; Naphthalenes; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cardiovascular disorders
  • Phase II Hypertension

Most Recent Events

  • 21 Sep 2022 Atorvastatin/aspirin/ramipril is still in preregistration for Cardiovascular disorders in Canada (PO) (Ferrer Internacional pipeline, September 2022)
  • 27 Aug 2022 Efficacy data from a phase III SECURE trial in Cardiovascular disorders released by Ferrer Internacional
  • 19 Feb 2020 Preregistration for Cardiovascular disorders in Canada (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top